Meridian Bioscience Reports Strong Fourth Quarter And Record Full-Year Fiscal 2021 Operating Results And Provides Fiscal 2022 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. ACN
2. SPCX
3. ABBV
4. DFTX
5. BAUFF
6. INTC
7. ICE
8. ELDN
9. KR
10. APGE

Go back to Meridian Bioscience Reports Strong Fourth Quarter And Record Full-Year Fiscal 2021 Operating Results And Provides Fiscal 2022 Guidance

Meridian Bioscience (VIVO) Tops Q4 EPS by 3c

November 12, 2021 7:32 AM EST

Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.23, $0.03 better than the analyst estimate of $0.20. Revenue for the quarter came in at $76.2 million versus the consensus estimate of $68.4 million.

GUIDANCE:

Meridian Bioscience sees FY2022 EPS of $0.98-$1.08, versus the consensus of $1.63.... More